<DOC>
	<DOC>NCT02082769</DOC>
	<brief_summary>The purpose of this study is to compare febuxostat allopurinol in subjects with gout.</brief_summary>
	<brief_title>Safety and Efficacy of Oral Febuxostat in Subjects With Gout</brief_title>
	<detailed_description>A randomized, double-blind, multicenter, allopurinol-controlled and parallel-assigned study comparing 40 mg, 80 mg of febuxostat, and allopurinol 300 mg in subjects with gout. Subjects will receive treatment for 24 weeks.</detailed_description>
	<mesh_term>Gout</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>Hyperuricemia (serum urate ≥8.0 mg/dL) and gout by Chinese Rheumatism Association Criteria; Renal function defined as a serum creatinine level of &lt; 2.0 mg/dL and creatinine clearance of &gt; 20 milliliters per minute (mL/min) by Cockcroft and Gault formula; No gout flare 2 weeks beforehand during 2week screening period. Pregnancy or lactation; Concurrent therapy with urate lowering agents, azathioprine, 6mercaptopurine, thiazide diuretics, or medications containing aspirin (&gt;325 mg) or other salicylates; Body Mass Index (BMI) &gt;50 kilogram per meter²(kg/m²); A history of active liver disease, or hepatic dysfunction; A history of bronchial asthma; A history of renal calculi or thyroid disease; Secondary gout Joint diseases induced by rheumatoid arthritis, psoriatic arthritis and bone tumor; Intolerance to allopurinol and Ibuprofen; Alcohol intake of ≥ 14 drinks/week; Clinically significant medical condition.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Gout</keyword>
	<keyword>Uric Acid</keyword>
	<keyword>Xanthine oxidase</keyword>
	<keyword>Febuxostat</keyword>
</DOC>